377220 — From Bio Co Balance Sheet
0.000.00%
- KR₩34bn
- KR₩65bn
- KR₩72bn
Annual balance sheet for From Bio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | ARS | ARS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 44,104 | 26,810 | 6,440 | 2,976 | 2,293 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4,454 | 3,561 | 3,034 | 3,123 | 2,608 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 71,717 | 53,560 | 37,653 | 29,013 | 18,127 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 20,333 | 33,309 | 47,027 | 45,991 | 45,218 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 96,414 | 93,823 | 97,364 | 81,176 | 65,245 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11,646 | 6,428 | 21,906 | 27,183 | 37,081 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 11,987 | 5,868 | 20,719 | 30,933 | 37,219 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 84,427 | 87,955 | 76,645 | 50,243 | 28,026 |
| Total Liabilities & Shareholders' Equity | 96,414 | 93,823 | 97,364 | 81,176 | 65,245 |
| Total Common Shares Outstanding |